MBC patients, who were carriers of BRCA2:c.7806-2A > G, did not experience higher incidence of other cancers, excluding non-melanoma skin cancer and contralateral breast cancer (22.2% vs. 23.6%, p = 1.0). This evidence concerns the gene BRCA2 and cancer.